Immatics (NASDAQ:IMTX) Short Interest Update

Immatics (NASDAQ:IMTX - Get Free Report) was the recipient of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 8,910,000 shares, a growth of 6.2% from the March 15th total of 8,390,000 shares. Based on an average daily volume of 526,500 shares, the days-to-cover ratio is currently 16.9 days.

Immatics Stock Down 0.2 %

Immatics stock traded down $0.02 during trading hours on Tuesday, hitting $10.38. The stock had a trading volume of 217,909 shares, compared to its average volume of 499,401. Immatics has a one year low of $6.31 and a one year high of $13.16. The stock has a market cap of $878.77 million, a price-to-earnings ratio of -7.98 and a beta of 0.67. The business's 50 day simple moving average is $11.52 and its 200-day simple moving average is $10.45.

Immatics (NASDAQ:IMTX - Get Free Report) last issued its quarterly earnings data on Thursday, March 21st. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.41) by $0.09. Immatics had a negative return on equity of 43.58% and a negative net margin of 179.67%. The company had revenue of $17.14 million during the quarter, compared to the consensus estimate of $11.78 million. Research analysts anticipate that Immatics will post -1.44 EPS for the current fiscal year.

Hedge Funds Weigh In On Immatics

Hedge funds have recently made changes to their positions in the stock. Wellington Management Group LLP increased its holdings in Immatics by 13.3% in the fourth quarter. Wellington Management Group LLP now owns 6,352,929 shares of the company's stock worth $66,896,000 after purchasing an additional 747,772 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in Immatics by 324.3% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,548,909 shares of the company's stock worth $16,310,000 after purchasing an additional 1,183,860 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in Immatics by 44.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,334,169 shares of the company's stock valued at $24,579,000 after acquiring an additional 719,634 shares during the period. Exome Asset Management LLC acquired a new stake in Immatics in the fourth quarter valued at approximately $1,368,000. Finally, Virtus ETF Advisers LLC grew its stake in Immatics by 14.3% in the fourth quarter. Virtus ETF Advisers LLC now owns 9,447 shares of the company's stock valued at $99,000 after acquiring an additional 1,184 shares during the period. 64.41% of the stock is currently owned by institutional investors.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.